Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | FDPS | P14324 | 6/20 | 0.55 |
| ▸ | LAP3 | P28838 | 2/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octyldodecanol SCHEMBL27938663 | 0.98 | LMNA (0.78) | LMNAALDH1A1FDPSLAP3SMPD1 | |
| Phosphoric Acid SCHEMBL27920099 | 0.98 | LMNA (0.78) | LMNAALDH1A1FDPSLAP3SMPD1 | |
| Phosphoric Acid SCHEMBL28401667 | 0.98 | LMNA (0.78) | LMNAALDH1A1FDPSLAP3SMPD1 | |
| Phosphoric Acid SCHEMBL28398553 | 0.96 | LMNA (0.75) | LMNAALDH1A1FDPSLAP3SMPD1 | |
| Phosphoric Acid SCHEMBL28403624 | 0.96 | LMNA (0.75) | LMNAALDH1A1FDPSLAP3SMPD1 | |
| Phosphoric Acid SCHEMBL29039767 | 0.94 | ALDH1A1 (0.62) | LMNAALDH1A1FDPSLAP3SMPD1 | |
| Phosphoric Acid SCHEMBL2356173 | 0.92 | LMNA (0.68) | LMNAALDH1A1FDPSLAP3SMPD1 | |
| Phosphoric Acid SCHEMBL28597917 | 0.89 | ALDH1A1 (0.58) | LMNAALDH1A1FDPSLAP3SMPD1 | |
| SCHEMBL4084151 | 0.89 | LMNA (0.95) | LMNAALDH1A1FDPS | |
| SCHEMBL22129709 | 0.89 | LMNA (0.95) | LMNAALDH1A1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3644948-B1 | ANHYDROUS SOLID COMPOSITION COMPRISING AN ISETHIONIC ACID DERIVATIVE, A GLUTAMIC ACID DERIVATIVE, AN AMPHOTERIC SURFACTANT AND FILLERS | OREAL (FR) | 2023-09-13 | — | — | EP | disclosed |
| US-20210137800-A1 | ANHYDROUS SOLID COMPOSITION COMPRISING AN ISETHIONIC ACID DERIVATIVE, A GLUTAMIC ACID DERIVATIVE, AN AMPHOTERIC SURFACTANT AND FILLERS | L'OREAL (FR) | 2021-05-13 | — | — | US | disclosed |
| US-10952953-B2 | Skin cleansing composition | L'OREAL (FR) | 2021-03-23 | — | — | US | disclosed |
| EP-3644948-A1 | ANHYDROUS SOLID COMPOSITION COMPRISING AN ISETHIONIC ACID DERIVATIVE, A GLUTAMIC ACID DERIVATIVE, AN AMPHOTERIC SURFACTANT AND FILLERSANHYDROUS SOLID COMPOSITION COMPRISING AN ISETHIONIC ACID DERIVATIVE, A GLUTAMIC ACID DERIVATIVE, AN AMPHOTERIC SURFACTANT AND FILLERS | L'Oréal (FR) | 2020-05-06 | — | — | EP | disclosed |
| US-20190021978-A1 | SKIN CLEANSING COMPOSITION | OREAL (FR) | 2019-01-24 | — | — | US | disclosed |
| WO-2019001940-A1 | ANHYDROUS SOLID COMPOSITION COMPRISING AN ISETHIONIC ACID DERIVATIVE, A GLUTAMIC ACID DERIVATIVE, AN AMPHOTERIC SURFACTANT AND FILLERSANHYDROUS SOLID COMPOSITION COMPRISING AN ISETHIONIC ACID DERIVATIVE, A GLUTAMIC ACID DERIVATIVE, AN AMPHOTERIC SURFACTANT AND FILLERS | L'OREAL (FR) | 2019-01-03 | — | — | WO | disclosed |
| EP-3393434-A1 | SKIN CLEANSING COMPOSITION | L'OREAL (FR) | 2018-10-31 | — | — | EP | disclosed |
| CN-108472222-A | Skin cleansing compositions | 欧莱雅 | 2018-08-31 | — | — | CN | disclosed |
| WO-2018114800-A1 | COMPOSITION COMPRISING AN AMPS POLYMER, MONTMORILLONITE, SILICA AND KAOLIN | L'OREAL (FR) | 2018-06-28 | — | — | WO | disclosed |
| CN-107949369-A | Cleasing compositions based on polyethylene glycol, polyether ester and polymer suspending agent | 莱雅公司 | 2018-04-20 | — | — | CN | disclosed |
| WO-2017108807-A1 | SKIN CLEANSING COMPOSITION | L'OREAL (FR) | 2017-06-29 | — | — | WO | disclosed |
| US-8758215-B2 | Applicator and a set including such an applicator | L'OREAL (FR) | 2014-06-24 | — | — | US | disclosed |
| US-8663614-B2 | Method of shaving using salicylic acid derivatives | L'OREAL (FR) | 2014-03-04 | — | — | US | disclosed |
| US-20110015463-A1 | APPLICATOR AND A SET INCLUDING SUCH AN APPLICATOR | L'OREAL (FR) | 2011-01-20 | — | — | US | disclosed |
| US-20100224204-A1 | METHOD OF SHAVING USING SALICYLIC ACID DERIVATIVES | L'OREAL (FR) | 2010-09-09 | — | — | US | disclosed |
| US-20080280797-A1 | Composition for caring for and/or removing makeup from keratinous substance(s) | L'OREAL (FR) | 2008-11-13 | — | — | US | disclosed |
| US-20080031843-A1 | Soap-free, self-foaming shaving gel comprising an N-acylsarcosine | L'OREAL (FR) | 2008-02-07 | — | — | US | disclosed |
| US-20060172904-A1 | Makeup-removing composition | L'OREAL (FR) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952953-B2 | Skin cleansing composition | C1S, C1R, DSG1 | LMNA 217/4885ALDH1A1 3151/4885FDPS 2813/4885 |
| US-20210137800-A1 | ANHYDROUS SOLID COMPOSITION COMPRISING AN ISETHIONIC ACID DERIVATIVE, A GLUTAMIC ACID DERIVATIVE, AN AMPHOTERIC SURFACTANT AND FILLERS | S100A4, KRT18, S100P | LMNA 1196/4885ALDH1A1 1414/4885FDPS 2305/4885 |
| US-20080031843-A1 | Soap-free, self-foaming shaving gel comprising an N-acylsarcosine | SOAT1, SGMS1, SOAT2 | LMNA 2487/4885ALDH1A1 1787/4885FDPS 802/4885 |
| US-20190021978-A1 | SKIN CLEANSING COMPOSITION | C1S, C1R, DSG1 | LMNA 217/4885ALDH1A1 3151/4885FDPS 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.